文献速递临床试验与 GCP

口服维生素D补充预防腹膜透析相关腹膜炎的效果:随机对照临床试验研究方案

The effects of oral vitamin D supplementation on the prevention of peritoneal dialysis-related peritonitis: study protocol for a randomized controlled clinical trial.
PubMed 文献 · Trials · 2019-11-28

本研究为前瞻性、开放标签、终点盲法的随机对照预试验,计划纳入30例近期腹膜炎已恢复的腹膜透析患者,按1:1随机分为口服维生素D 2000 IU/日组与不补充维生素D组,随访12个月,主要评估开展大规模随机对照试验的可行性(招募、保留、依从性、安全性)及保真度(血清25-羟基维生素D水平变化)。

要点

  • 维生素D缺乏与腹膜透析相关腹膜炎密切相关,但补充维生素D能否降低腹膜炎风险尚需随机对照试验验证。
  • 本预试验纳入30例近期腹膜炎已恢复的腹膜透析患者,随机分为口服维生素D 2000 IU/日组与不补充组,随访12个月。
  • 主要结局为开展大规模随机对照试验的可行性及保真度,次要结局包括腹膜炎发生时间、恢复、转血液透析及腹膜炎相关死亡。

核心结论

  • 这是首个探讨维生素D补充对腹膜透析患者后续腹膜炎风险影响的随机对照试验。
  • 本预试验结果将决定能否开展全规模随机对照试验,后者可能为预防腹膜透析相关腹膜炎提供新策略。

研究设计与样本

  • 前瞻性、开放标签、终点盲法的随机对照预试验,旨在评估口服维生素D补充的可行性并探索其对后续腹膜透析相关腹膜炎风险的影响。
  • 纳入近期腹膜炎已恢复的腹膜透析患者,按1:1随机分为口服维生素D补充组(2000 IU/日)与不补充维生素D组(对照组),两组均按国际腹膜透析学会指南接受常规治疗。
  • 两组样本量均为30例,所有参与者随访12个月。
  • 试验注册:ClinicalTrials.gov,NCT03264625,注册日期2017年8月29日。

主要发现

  • 主要结局为评估未来开展大规模随机对照试验以确定维生素D对腹膜透析相关腹膜炎风险影响的可行性(招募成功、保留、依从性、安全性)及保真度(随访期间血清25-羟基维生素D水平变化)。
  • 次要结局包括腹膜炎发生时间、腹膜炎恢复、腹膜炎相关转血液透析及腹膜炎相关死亡(定义为腹膜炎发病30天内死亡)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Vitamin D deficiency has been shown to be closely associated with peritoneal dialysis (PD)-related peritonitis. The aim of this study is to examine the feasibility of conducting a large, powered randomized controlled trial to determine the effects of vitamin D supplementation on the risk of PD-related peritonitis in patients who have already experienced an episode of peritonitis. METHODS: This prospective, open-label randomized controlled pilot trial with blinded end-points aims to determine the feasibility of oral vitamin D supplementation and to explore its effects on the risk of subsequent PD-related peritonitis among PD patients who have recovered from a recent episode of peritonitis. Eligible patients will be randomized 1:1 to either oral vitamin D supplementation (2000 IU per day; intervention group) or no vitamin D supplementation (control group) in addition to usual care according to International Society for Peritoneal Dialysis guidelines. The sample size will be 30 patients for both groups. All participants will be followed for 12 months. The primary outcome is the assessment of feasibility (recruitment success, retention, adherence, safety) and fidelity (change in serum 25-hydroxyvitamin D level during follow-up) for a large, powered randomized controlled trial to determine the effects of vitamin D on the risk of PD-related peritonitis in the future. Secondary outcomes include time to peritonitis occurrence, recovery of peritonitis, peritonitis-related transition to hemodialysis, and peritonitis-related death (defined as death within 30 days of peritonitis onset). DISCUSSION: This is the first randomized controlled trail investigating the effects of vitamin D supplementation on the risk of subsequent PD-related peritonitis among patients on PD. The findings for this pilot study will determine the feasibility of conducting a full-scale randomized controlled trail, which may provide a new strategy for preventing PD-related peritonitis among PD patients. TRIAL REGISTRATION: Clinicaltrails.gov, NCT03264625. Registered on 29 August 2017.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Zhang YH, Xu X, Pi HC, et al. The effects of oral vitamin D supplementation on the prevention of peritoneal dialysis-related peritonitis: study protocol for a randomized controlled clinical trial. Trials. 2019. PMID: 31779675. doi:10.1186/s13063-019-3784-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。